Comprehensive safety review of GLP-1 RAs covering GI effects (nausea, vomiting), pancreatitis, thyroid concerns, NAION, bile duct signals, and mental health, with evidence-based risk management strategies.
Complete safety mapThe definitive GLP-1 safety review covers every concern from common GI effects to rare signals like NAION and bile duct cancer — with management strategies for each
What the researchers found
Comprehensive GLP-1 RA safety review: GI (common, manageable), pancreatitis (monitoring), thyroid (reassuring), NAION (low absolute risk), bile duct (investigating), mental health (safe), musculoskeletal (variable). Evidence-based management for each.
Why it matters
The most comprehensive GLP-1 safety review to date — essential reading for every prescriber.
How the study worked
State-of-the-art safety review of all GLP-1 RA adverse effects and emerging safety signals with evidence-based risk management.
What this study cannot tell us
Comprehensive review. Some emerging signals have limited data.
How to read the evidence
State-of-the-art comprehensive safety review.
When this study was published
Published in 2025.
The bigger picture
Comprehensive safety knowledge enables confident prescribing of GLP-1 drugs to the millions who benefit from them.
Questions still open
- Which safety signals will prove clinically significant?
- Should safety monitoring protocols be standardized?
- Do newer GLP-1 drugs have different safety profiles?
Common questions
What are all the known side effects of GLP-1 drugs?
Are GLP-1 drugs safe overall?
Read the original research
Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review.
Drugs, 86(1), 11-36
Citation
Kunutsor, Setor K; Seidu, Samuel. (2026). Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review.. Drugs, 86(1), 11-36. https://doi.org/10.1007/s40265-025-02263-0